This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Relapsed and Refractory Multiple Myeloma
and you are
over 18
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of this study is to evaluate the safety, tolerability and overall response rate of carfilzomib in combination with dexamethasone for the treatment of multiple myeloma in China.

Provided treatments

  • Drug: Dexamethasone
  • Drug: Carfilzomib
Tris trial is registered with FDA with number: NCT03029234. The sponsor of the trial is Amgen and it is looking for 126 volunteers for the current phase.
Official trial title:
An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China